Clarivate Epidemiology’s coverage of overactive bladder (OAB) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Clarivate Epidemiology’s coverage of overactive bladder (OAB) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Clarivate Epidemiology’s coverage of the meningococcal B vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of hospital-treated gram-positive infections (HT-GPIs) comprises epidemiological estimates of nine types of infections—urinary tract infections (UTIs),…
Clarivate Epidemiology’s coverage of BRAF comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
Clarivate Epidemiology’s coverage of the RSV vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…
Clarivate Epidemiology’s coverage of the RSV vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China,…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in Europe (Austria, Belgium, Czech Republic, Denmark,…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in the Asia-Pacific (Australia, Hong Kong, Taiwan,…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in the Middle East and Africa (Egypt, Nigeria, Saudi Arabia…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia,…
Clarivate Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of RAS comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of acute musculoskeletal pain (AMP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States…